BioNotebook: Versartis VC funding, IPO filing; ANI 2013 earnings; Cardiome's ATM; Eleven's Phase III
This article was originally published in Scrip
Executive Summary
Growth hormone developer Versartis announced a $55m Series E venture capital funding round on the morning of 18 February then filed for an $80m initial public offering after the stock market closed.